| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MET |
| Uniprot No | P08581 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 956-1390aa |
| 氨基酸序列 | KKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRA TFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDL SALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKI HCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLV VLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDL AARNCMLDEKFTVKVADFGLARNMYDKEYYSVHNKTGAKLPVKWMALESL QTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQP EYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNAT YVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS |
| 预测分子量 | 81 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MET重组蛋白的3-4篇参考文献及其摘要概括：
1. **"Crystal structure of the MET ectodomain in complex with the hepatocyte growth factor"**
- **作者**: Gherardi, E., et al.
- **摘要**: 该研究解析了MET受体胞外结构域与肝细胞生长因子(HGF)结合的晶体结构，通过重组蛋白技术阐明了两者相互作用的分子机制，为靶向MET的抑制剂设计提供了结构基础。
2. **"MET signalling: ligand-dependent activation and receptor crosstalk"**
- **作者**: Comoglio, P.M., et al.
- **摘要**: 综述了MET受体酪氨酸激酶的信号通路，包括HGF依赖的激活机制及与其他受体(如EGFR)的交叉调控，涉及重组MET蛋白在体外信号传导实验中的应用。
3. **"Development of a recombinant MET protein-based assay for high-throughput inhibitor screening"**
- **作者**: Liu, Y., et al.
- **摘要**: 提出一种基于重组MET激酶域的高通量筛选方法，用于快速鉴定MET小分子抑制剂，并验证其在癌症细胞模型中的抗肿瘤活性。
4. **"Structural and functional characterization of a monovalent MET agonist antibody"**
- **作者**: Jin, H., et al.
- **摘要**: 利用重组MET蛋白研究单价抗体对MET的激活作用，揭示其通过二聚化诱导受体信号传导的机制，为组织再生治疗提供了新策略。
这些文献涵盖了MET重组蛋白在结构生物学、信号通路研究、药物开发及治疗应用中的关键作用。
MET, a receptor tyrosine kinase encoded by the *MET* proto-oncogene, plays a pivotal role in regulating cellular processes such as proliferation, migration, and survival. It is activated by its ligand, hepatocyte growth factor (HGF), initiating downstream signaling pathways like MAPK/ERK and PI3K/AKT. Dysregulation of MET signaling—through overexpression, gene amplification, or mutations—is strongly implicated in tumorigenesis, metastasis, and drug resistance across cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma.
Recombinant MET proteins are engineered versions of the MET receptor or its domains, produced using expression systems like mammalian, insect, or bacterial cells. These proteins typically retain functional epitopes for ligand binding or antibody recognition, enabling applications in drug discovery and biomedical research. For instance, MET extracellular domain (ECD) recombinants are widely used to study HGF-MET interactions, screen therapeutic antibodies, or develop diagnostic assays. Fc-fused MET variants enhance stability and simplify detection in binding studies.
In therapeutic development, MET recombinant proteins serve as critical tools for validating MET-targeted therapies, such as tyrosine kinase inhibitors (TKIs) or monoclonal antibodies. They also aid in elucidating resistance mechanisms, such as MET amplification in EGFR inhibitor-resistant NSCLC. Additionally, MET recombinants are employed in structural studies to resolve MET-HGF complex architectures, guiding the design of next-generation inhibitors.
Overall, MET recombinant proteins bridge basic research and clinical translation, offering insights into MET biology and accelerating the development of precision oncology therapies. Their versatility underscores their importance in understanding MET-driven pathologies and advancing targeted cancer interventions.
×
